Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its participation in the Goldman Sachs 42nd Annual Global Healthcare Conference, scheduled for June 8, 2021, at 9:40 a.m. Eastern Time. The presentation will be available via a live webcast on the company's website, with a replay accessible for 14 days post-event. Kiniksa focuses on developing therapeutic medicines for patients with significant unmet medical needs, with products including ARCALYST (rilonacept) and others designed to target immunological pathways.
- None.
- None.
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts!™
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
FAQ
When is Kiniksa's presentation at the Goldman Sachs Healthcare Conference?
How can I access the live webcast of Kiniksa's presentation?
What is the duration for the replay of Kiniksa's conference presentation?
What therapeutic areas does Kiniksa Pharmaceuticals focus on?
What are some products developed by Kiniksa Pharmaceuticals?
